Tag: Pfizer/Flynn
First of All, Do No Harm: New Directions in EU Antitrust...
The recent Paroxetine and CMA v. Pfizer/Flynn cases confirm the EU approach to pay-for-delay, respectively establish a workable approach to excessive pharmaceutical pricing at...
